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ABSTRACT
Introduction We present practical metrics for estimating 
the expected health benefits of specific research 
proposals. These can be used by research funders, 
researchers and healthcare decision- makers within low- 
income and middle- income countries to support evidence- 
based research prioritisation.
Methods The methods require three key assessments: 
(1) the current level of uncertainty around the endpoints 
the proposed study will measure; (2) how uncertainty 
impacts on the health benefits and costs of healthcare 
programmes and (3) the health opportunity costs imposed 
by programme costs. Research is valuable because it 
can improve health by informing the choice of which 
programmes should be implemented. We provide a 
Microsoft Excel tool to allow readers to generate estimates 
of the health benefits of research studies based on these 
three assessments. The tool can be populated using 
existing studies, existing cost- effectiveness models and 
expert opinion. Where such evidence is not available, the 
tool can quantify the value of research under different 
assumptions. Estimates of the health benefits of research 
can be considered alongside research costs, and the 
consequences of delaying implementation until research 
reports, to determine whether research is worthwhile. We 
illustrate the method using a case study of research on HIV 
self- testing programmes in Malawi. This analysis combines 
data from the literature with outputs from the HIV synthesis 
model.
Results For this case study, we found a costing study 
that could be completed and inform decision making 
within 1 year offered the highest health benefits (67 000 
disability- adjusted life years (DALYs) averted). Research on 
outcomes improved population health to a lesser extent 
(12 000 DALYs averted) and only if carried out alongside 
programme implementation.
Conclusion Our work provides a method for estimating 
the health benefits of research in a practical and timely 
fashion. This can be used to support accountable use of 
research funds.
INTRODUCTION
Globally, significant resource and effort is 
spent on health- related research with the 
10 largest public and philanthropic funders 
spending US$37.1 billion in 2013.1 An impor-
tant component of this funding is dedicated 
to basic science and preclinical research. 
However, much research aims to better 
understand current epidemiological patterns, 
healthcare provision and patient outcomes, 
and how they would be impacted by alternative 
interventions with a view to informing health-
care investments in the near- term. Clinical 
trials, surveillance programmes, cost studies, 
morbidity surveys and implementation studies 
all serve this purpose. By improving the infor-
mation available to support investment deci-
sions, they have the potential to improve 
population health. However, research is costly 
and those funding research have constraints 
on their ability to expand research budgets. 
This raises the question of which research 
activities should be prioritised.
Key questions
What is already known?
 ► Methods are available to estimate the value of re-
search studies but are not widely understood, ap-
preciated or applied.
What are the new findings?
 ► We provide a method and companion Microsoft 
Excel tool that can be used to estimate the health 
benefits of research studies without using advanced 
value of information methods.
 ► The tool can be populated using a range of evidence 
or used to test how different assumptions affect the 
value of research.
 ► We illustrate the method by applying it to estimate 
the value of research studies on HIV self- testing 
programmes.
What do the new findings imply?
 ► Our work provides a method for estimating the 
health benefits of research in a practical and timely 
fashion; these estimates can be considered along-
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To answer this question there is a need to understand 
why evidence is valuable to healthcare systems and the 
populations they serve, and how to assess the value of 
specific research proposals. This has been recognised 
by a number of stakeholders and a set of methods called 
value of information analysis allow the value of specific 
research proposals to be quantified.2–4 Value of informa-
tion analysis has been applied in a range of contexts in 
high- income settings, for example, to assess the value of 
clinical trials of interventions for which limited evidence 
exists.5 6 Previous studies have also estimated the value 
of further research in low- income and middle- income 
countries (LMICs).4 7 8 These studies used advanced 
methods4 7 8 that require specific types of analyses to 
have been conducted (probabilistic analyses of a model 
already addressing the policy question of interest).9 10 
The application of value of information analysis to help 
prioritise research has, therefore, been limited as the 
advanced methods required are often not practical given 
time and resource constraints, and computation may be 
impractical where transmission models are required to 
represent disease dynamics.
In this paper, we use a graphical method and simple 
metrics to show how the principles of value of informa-
tion analysis can be applied in these common but chal-
lenging circumstances. We provide a simple excel tool 
to facilitate use of the method and explain how the 
method can be applied using different types of evidence 
including typical outputs from existing cost- effectiveness 
models. We also discuss how this type of analysis can 
inform key policy questions relating to the allocation 
of research funds. We then apply this method in a case 
study assessing the value of research in HIV self- testing 
programmes in Malawi.
The methods presented are relevant to any party with 
a stake in ensuring health research funds are used in 
a way that is expected to improve population health. 
This includes research funders, researchers and health-
care decision- makers within LMICs who rely on robust 
evidence to make investment decisions. The latter 
group includes individuals within ministries of health 
charged with prioritising health programmes (including 
designing health benefits packages), and other decision- 
makers at a regional and national level who are respon-
sible for healthcare resource allocation. The methods 
presented apply where a single budget is used to fund 
research and service provision, and to the more common 
situation where budgets for these activities are separate.
METHODS
Graphical illustration using a simple quantitative tool to 
quantify the value of research
Cost- effectiveness analyses are routinely used to assess 
whether a programme is expected to improve popula-
tion health once the health opportunity costs imposed 
by additional programme spending are accounted for. 
This assessment can be summarised using an estimate 
of the net disability- adjusted life years (DALYs) averted 
by the programme. This reflects both the health bene-
fits of the programme and an assessment of the health 
forgone as funding a programme means that resources 
will be unavailable for the delivery of other programmes. 
This is calculated as the DALYs directly averted via the 
programme minus the DALYs incurred elsewhere in the 
health system due to the additional programme funding 
required.
In the same way, we can quantify the net DALY impact 
of investing in healthcare provision, we can also quantify 
the net DALY impact of investing in research. This idea is 
the basis for value of information analysis.
To assess the value of a research study or other data 
collection or evidence gathering activities, we need 
to understand the types of uncertainty that we could 
examine in a study with particular endpoints. These 
endpoints may be epidemiological, clinical, patient 
reported, process related or economic. For example, we 
might be uncertain about the effectiveness of a drug, 
the uptake of a rural community- based prevention 
programme, the quality of life of people with different 
treatment outcomes, or the cost of implementing a new 
diagnostic pathway. To assess the value of improving infor-
mation relating to an endpoint, we need to understand 
our current level of uncertainty about the endpoint given 
existing evidence. This uncertainty can be described by a 
probability distribution showing the likelihood that the 
endpoint takes different values. This distribution is often 
called a prior, since it is based on existing knowledge of 
uncertainty about the specific endpoint. Figure 1B shows 
the prior on an uncertain endpoint as a histogram.
Uncertainty about the endpoint alone is not suffi-
cient to justify expenditure on research. For research 
to deliver value, the uncertainty in the endpoint must 
translate to uncertainty about whether the programme 
is cost- effective. For example, we might be highly uncer-
tain about a programme’s effects on clinical outcomes. 
However, if the programme is cost- effective across 
the range of plausible clinical outcomes then further 
research on this endpoint may not deliver value in this 
setting as it would not change the decision about funding 
the intervention.
We can assess whether uncertainty in the endpoint is 
likely to translate to uncertainty about cost- effectiveness 
by estimating the net DALYs we would expect to avert 
if the endpoint was found to take the different values 
reflected in the prior. This is shown in figure 1A. In this 
illustration, as the endpoint increases, the net DALYs 
averted increase. This reflects estimates of how both 
DALYs averted and additional costs (or cost savings) 
change with the value of the endpoint. It also reflects a 
measure of the health opportunity cost of financing the 
programme, as this allows the additional costs of the 
programme to be converted to health foregone.
The mean value of the endpoint represents our ‘best 
guess’ of the value the endpoint takes given currently 
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by the programme are positive and the programme 
would be considered cost- effective. However, below a 
certain ‘trigger’ value of the endpoint, the net health 
effects of the programme become negative, that is, the 
programme is not cost- effective. The shaded area of the 
prior histogram (figure 1B) indicates the probability 
that the endpoint will fall below the trigger point. This 
is the probability that the intervention will turn out not 
to be cost- effective and that implementation will reduce 
population health. However, if we conduct research to 
improve our understanding of the endpoint this is the 
probability that the research could change the imple-
mentation decision. If it is considered implausible that 
the endpoint could take a value as extreme as the trigger 
point then further research will not result in a change in 
decision and, therefore, based on the available evidence, 
may not be considered an appropriate use of resources. 
This emphasises that we should care about uncertainty in 
endpoints when it leads to uncertainty in decisions.
Without additional research, on average implementa-
tion averts DALYs but if low values of the endpoint are 
realised, implementation reduces population health. If 
research is conducted and indicates that the endpoint 
falls below the trigger point (i.e. the programme is not 
cost- effective), then the programme will not be imple-
mented. Research therefore avoids the health losses 
associated with programme implementation under these 
conditions as shown by the grey bars in figure 1A. These 
bars, therefore, represent the potential health gains from 
research. The expected net DALYs averted via research 
are calculated as the health gains (resulting from avoided 
health losses) when the endpoint takes values below 
the trigger point, that is, the shaded bars in figure 1A 
weighted by the probability of the quantity taking each 
value below the trigger point, that is, the shaded bars in 
figure 1B.
Figure 1C, D show how the value of research can be 
calculated when the programme is not expected to be 
cost- effective based on current information. Without 
further research the programme is not implemented and 
no population health gains are generated. With further 
research, there is a possibility that the endpoint will take 
values sufficiently high to support implementation and 
net DALYs are averted. The possible health gains from 
research are again shown by the grey bars (figure 1C).
This method shows the value of completely eliminating 
the uncertainty around the endpoint. Although in reality 
further research will not resolve all uncertainty, the esti-
mates generated provide an expected upper bound for 
the population health benefits from research for the 
setting of interest.
We express the value of the research proposals using 
two different metrics. The first is the net DALYs averted 
by using the research to improve decision making. Where 
a research study is expected to be used in a number of 
countries, the approach described above can be applied 
for each country and the net DALYs averted across coun-
tries can be calculated. Individual country estimates of 
the net DALYs averted by research are likely to differ for 
a range of reasons including differences in the size of the 
population that stand to benefit from research, the costs 
and health benefits of the programme and the health 
opportunity costs of healthcare funds.
The net DALYs averted by research provides an esti-
mate of the expected maximum population health gains 
from research accounting for both health gains and 
programme costs, but it does not consider research costs. 
Funding a specific research proposal has opportunity 
Figure 1 Calculating the net health effects of research. Legend: (A) shows net disability- adjusted life years (DALYs) averted 
by the programme for different values of the endpoint of interest when the programme is expected to be cost- effective based 
on current evidence; (B and D) show the prior on the uncertain endpoint; (C) shows net DALYs averted by the programme 
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costs, which are the health gains that could be generated 
by using this funding for other research studies.
The second metric is, therefore, the maximum 
amount a research funder should be willing to spend 
on the research, given its estimated net health effects. 
This metric is estimated by multiplying the net DALYs 
averted by research by a measure of the opportunity cost 
of research funds. We assume that research funds have 
similar levels of opportunity costs as funds for service 
provision. For example, if a research study is expected to 
avert 1000 DALYs and our measure of opportunity costs 
indicates that every US$500 of expenditure results in an 
additional 1 DALY being incurred elsewhere in the health 
system, then the maximum a research funder should be 
willing to spend on the research would be US$500 000. If 
they spend more than this the health opportunity costs of 
funding the research would exceed 1000 DALYs and thus, 
more than outweigh the net health gains from research. 
Given the very different sources of funding that typically 
underpin service provision and research, the opportunity 
cost of research funds may differ from the opportunity 
cost of service funding. We will return to the question 
of how the opportunity cost of research funds could be 
estimated in the discussion.
To illustrate the approach, we use a numeric example 
where we are interested in an outcomes endpoint that 
can, in principle, take different values between 0 and 1 
(eg, the probability of treatment response). Our existing 
knowledge of the endpoint indicates it is expected to 
take a value of 0.10 (SE 0.04, 95% CI 0.04, 0.19), which 
allows us to define its prior (we apply a beta distribution 
here). In a second step, we make use of existing informa-
tion about how different values of the endpoint influence 
health effects and costs of the programme. In the present 
example, we know that if the endpoint takes the average 
value, the programme is expected to avert 2000 DALYs. If 
the endpoint takes the value at the lower bound of the CI 
the programme is expected to avert 1000 DALYs, whereas 
if the endpoint takes the value at the higher bound of 
the CI, the programme is expected to avert 3000 DALYs. 
The expected additional long- term cost associated with 
the programme is US$450 000 and is not expected to vary 
with the endpoint. Lastly, we evaluate the health opportu-
nity cost associated with funding the intervention. This is 
1500 DALYs based on additional costs of US$450 000 and 
an estimate of health opportunity cost of US$300/DALY. 
This information about the DALYs averted at different 
values of the endpoint, and about opportunity costs, 
allows us to estimate the net DALYs averted at different 
values of the endpoint. We provide a simple Microsoft 
Excel tool to allow users to review the numeric example 
and apply the approach to their own contexts. This tool 
is available in the online supplementary material, for 
the most up to date version of the tool see https://www. 
york. ac. uk/ che/ research/ global- health/ methods- guide-
lines/# tab- 4. The tool provides a graphical summary of 
the prior information and the relationship between net 
health effects and the endpoint of interest as shown in 
figure 2.
The tool uses regression methods to generate estimates 
of the net health effects of a programme at all plausible 
values of the endpoint. The regression uses estimates of 
DALYs averted and additional costs at different values of 
the endpoint that are entered by the user. Two regres-
sions are then fitted, one regressing DALYs averted on the 
endpoint and the other regressing additional costs on the 
endpoint. Options are available to use linear regression, 
or to assume range of non- linear relationships between 
the endpoint and DALYs averted or additional costs.
The tool uses the data entered to generate estimates 
of the benefits of research. The tool shows the implica-
tions of making decisions based on current evidence, 
and the potential benefits of making decisions on the 
basis of further research as shown in figure 2. Without 
further research we can only base our decision on what 
we expect to occur. We expect that the programme averts 
1868 DALYs (the expected health benefits (1868) are not 
identical to the health benefits at the mean value of the 
endpoint (2000) as the beta distribution used to describe 
the endpoint is not symmetrical) with a health opportu-
nity cost of 1500 DALYs, that is, 368 net DALYs averted. 
On this basis, we implement the programme based on 
current evidence. If we conduct research, we will gain 
more information about which value the endpoint 
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takes. If the endpoint is as expected or higher, there is 
no change to the decision. If the endpoint is lower than 
the trigger point of 0.07, the net DALYs averted become 
negative and we choose not to implement the interven-
tion. Weighting the probability of observing values of the 
endpoint below 0.07 by the net DALYs averted by avoiding 
implementation, we expect the research to avert 59 
DALYs. If the research is only considered relevant in this 
context then the maximum a research funder should be 
willing to spend on the research is US$17 800, suggesting 
that this may not be a high priority area for research. If 
the research is expected to inform decision making in 
other countries, then the process can be repeated for 
each country, and the value of research across countries 
can be calculated.
Guidance for gathering evidence to inform estimates of the 
value of research
As shown above, a necessary part of any assessment of 
the value of research is formulating a view on the current 
level of uncertainty about the endpoints the research will 
examine. This uncertainty can be represented as a prior 
distribution. Evidence from existing studies including 
pilot studies or systematic reviews can be used to formu-
late priors. In practice, however, many research studies 
examine combinations of interventions and contexts 
which have not previously been studied. When evalu-
ating a specific research proposal formally elicited expert 
opinion11 12 may, therefore, be valuable to complement 
quantitative and qualitative information to formulate 
priors.
It is also necessary to estimate how the health benefits 
and additional costs of the programme change with the 
endpoint. Where a cost- effectiveness model is available, 
this can be obtained by conducting one- way sensitivity 
analysis, that is, varying the values taken by the endpoint 
of interest and recording the corresponding variations in 
health benefits and additional long- term costs associated 
with the intervention. If a cost- effectiveness model is not 
available for the context of interest, or existing models 
cannot be easily adapted, then formal expert elicitation 
can be used to quantify the magnitude of health benefits 
and additional costs at different levels of the endpoint.
In order to estimate the net health effects of 
programmes, we require an understanding of how addi-
tional programme costs translate to health opportunity 
costs. Recent work has estimated the opportunity cost 
of domestic healthcare spending in a wide range of 
LMICs.13 Where programmes are funded via overseas aid 
the opportunity costs of this funding will depend on the 
remit of the funder. An understanding of the potential 
health opportunity cost of an overseas aid funding stream 
can be garnered by reviewing the cost- effectiveness 
of those interventions that are and are not currently 
funded, and potentially developing a cost- effectiveness 
league table of funded programmes.
Specification of each element described above is likely 
to require judgements regarding which evidence is 
relevant and how to use that evidence. By using the tool 
provided, users can explore the sensitivity of their results 
to each of these elements. In some contexts, the time- 
sensitive nature of a research- funding decision, analyst 
capacity or funding availability, may make it infeasible 
to assemble these types of evidence. In these contexts, 
the tool can provide a quantitative basis for testing how 
different assumptions influence both the net DALYs 
averted by the research and the maximum amount a 
funder should be willing to spend on the research.
We now show how the approach can be applied to a 
specific example. In this example, evidence is available 
from a cost- effectiveness model but no probabilistic sensi-
tivity analysis has been conducted thus prohibiting use of 
standard value of information methods.
Self-testing example using the HIV synthesis model
We show how these methods can be applied to assess 
the value of research in HIV self- testing programmes in 
Malawi. Self- testing programmes have been the subject 
of a number of recently published and ongoing research 
studies in sub- Saharan Africa (for some examples see 
refs. 14–18). We use the HIV synthesis model19 20 which 
has been used to assess the cost- effectiveness of a range of 
HIV prevention and treatment investments in different 
settings. The self- testing programme under evaluation 
is not currently part of the HIV investment strategy. We 
assess two possible scenarios to estimate the population 
health benefits from research studies on self- testing 
programmes. Under the first scenario, no research is 
conducted and investment in self- testing is based on 
current evidence about the costs and benefits of the 
programme. Under the second scenario, research is 
commissioned and the results of the research inform the 
decision about investment in self- testing.
Studies of HIV testing have included a range of 
endpoints measuring intervention effectiveness and costs 
at different points in the cascade of care. Frequently 
reported endpoints include coverage and uptake, HIV 
positivity, linkage and retention in care, and programme 
costs.18 The cost- effectiveness of self- testing is strongly 
linked to the cost per new HIV diagnosis21 which is calcu-
lated as the programme cost per person divided by the 
proportion of people diagnosed with HIV as a result 
of the programme. This suggests that two endpoints: 
programme costs and the proportion of people diag-
nosed with HIV, are likely to be important determi-
nants of whether testing is cost- effective and therefore 
important targets for further research. The proportion 
of people diagnosed with HIV within facility- based care 
as a proportion of those targeted for testing reflects the 
combined effect of multiple endpoints collected within 
testing studies such as uptake, HIV positivity within those 
tested and linkage to facility- based care. We, therefore, 
examine a cost study focused on the cost of the self- 
testing programme per individual eligible for testing; 
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the eligible population who are diagnosed with HIV in 
facility- based care.
To evaluate the research proposals, we require priors 
describing the uncertainty about both programme costs 
and the proportion of the eligible population who are 
diagnosed with HIV in facility- based care. These priors 
will depend on the characteristics of the target popula-
tion and implementation setting, the details of the testing 
programme such as whether measures to enhance linkage 
are proposed (eg, financial incentives, community- based 
support) and other contextual factors. The priors will, 
therefore, depend on the exact details of a specific 
research proposal and are most likely best formulated 
by combining available data, qualitative information and 
expert opinion. For the purposes of this demonstration, 
we use only data from the literature to inform the priors. 
We use data from a systematic review and meta- analysis,18 
focusing on those data relating to self- testing. This work 
reflects the fairly limited data on self- testing available in 
2015, when many of the self- testing studies were designed. 
For further details see online supplementary material S1.
Estimates of the additional costs and DALYs averted 
by a self- testing programme were derived from the HIV 
synthesis model. This is an individual- based stochastic 
model of heterosexual transmission, progression and 
treatment of HIV infection. We used outputs from the 
model generated by the ‘Working group on cost effective-
ness of HIV testing in low income settings in sub- Saharan 
Africa’21 which examined the effects of expanding HIV 
testing beyond a core testing programme considered 
to represent current standard of care in many coun-
tries. This core testing programme included testing 
for: pregnant women, symptomatic individuals, female 
sex workers (although this is not fully implemented in 
many countries) and men coming forward for circumci-
sion. This work examined the relationship between cost 
per HIV diagnosis and long- term cost effectiveness. The 
demographics of the population and the HIV epidemic 
features were based on those for Malawi and the model is 
calibrated to data that are representative of this setting. 
This work examined the cost- effectiveness of testing for 
a wide range of scenarios. The scenarios reflect variation 
in the expanded testing programme testing rates, how 
well the programme targets HIV positive individuals and 
cost per test. The scenarios also reflect uncertainty about 
the context in which the programme is implemented in 
terms of the nature of the epidemic, ART programme 
characteristics and the core testing programme. The 
model time horizon was 50 years and a discount rate of 
3% was used for costs and outcomes.
We used the scenario analysis outputs from the model 
to estimate the relationship between costs and DALYs 
averted and both endpoints of interest (the proportion 
of the targeted population diagnosed with HIV in facility- 
based care and programme costs). For further details, see 
online supplementary material S2.
Estimating the net DALYs averted by self- testing, requires 
a measure of the health opportunity cost of the funds used 
to pay for self- testing. We have used a measure of oppor-
tunity cost of US$500/DALY. This represents the cost per 
DALY averted of those services we expect to be displaced 
by investments in self- testing. US$500/DALY is considered 
a relevant cost- effectiveness threshold for resource alloca-
tion within the HIV programme which is overwhelmingly 
reliant on overseas aid.21 22 Additionally, HIV investments 
which Malawi and other countries in sub- Saharan Africa 
have struggled to scale up often have incremental cost- 
effectiveness ratio (ICERs) around US$500/DALY, and 
HIV budgets have been shown to be exhausted in South 
Africa after funding interventions with ICERs around 
US$500/DALY.23 Where delivery of HIV interventions 
draws on resources that would otherwise be used for non- 
HIV health activities a lower threshold is more appropriate, 
we return to this in the discussion.
The analysis of the outputs from the HIV synthesis 
model were conducted in the statistical software R and 
associated packages.24–39
Table 1 Population health consequences of 
implementation without and with additional research for the 
HIV self- testing case study
Implications of decision 
making without further 
research
Expected DALYs averted by 
programme
1 884 832
Expected additional long- 
term costs associated with 
programme
US$888 203 454
Expected health opportunity 
costs of funding programme 
(DALYs incurred)
1 776 407
Incremental cost- effectiveness 
ratio (US$/DALY)
US$471
Expected net DALYs averted by 
implementation
108 425
Implications of decision 
making informed by further 
research
Outcomes study   Cost study
Value of endpoint at which 
decision changes*
0.05† US$9.98‡
Probability further research 
could change decision
0.33 0.33
Expected net DALYs averted 
via research
41 740 89 375
Potential maximum expenditure 
on study
US$20 870 062 US$44 687 606
Total expected net DALYs 
averted
150 165 197 800
*The units for this row are the proportion of the targeted population 
who are diagnosed with HIV in facility- based care for the outcomes 
study and the cost per person tested in US$ for the cost study.
†This indicates that expanded testing is no longer cost- effective if the 
proportion of the population who are diagnosed with HIV and linked to 
care is below 0.05.
‡This indicates that expanded testing is no longer cost- effective if the 
cost of testing exceeds US$9.98 per individual eligible for testing.
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RESULTS
The implications of making decisions about the self- 
testing programme based on current evidence are shown 
in table 1. The self- testing programme is cost- effective as 
indicated by the ICER falling below the cost- effectiveness 
threshold of US$500/DALY averted and positive values 
for net DALYs averted. These results represent the 
expected net health effects of the programme. However, 
due to uncertainties in the evidence base, there is a 
possibility that self- testing is not cost- effective and in 
this case, implementing it will reduce net population 
health. Further research may, therefore, be of value to 
better understand the cost- effectiveness of the self- testing 
programme. Figure 3 shows how the principles outlined 
in figures 1–2 can be applied to quantify the implica-
tions of decision making based on further research on 
outcomes. The net DALYs averted by the self- testing 
programme increase as the proportion of people diag-
nosed with HIV increases (figure 3A). At the mean value 
of the outcome endpoint, the programme delivers net 
health gains (108 400 averted DALYs). If the proportion 
of people diagnosed with HIV is less than the trigger 
point of 0.05, then self- testing is no longer cost- effective. 
The probability that the outcome endpoint is below this 
trigger value is shown by the shaded area in figure 3B 
(probability of 0.33). If the outcome study is commis-
sioned then this would avoid the programme being 
implemented in these circumstances. The avoided poten-
tial waste of healthcare resources can be translated into 
population health gain as indicated by the grey shaded 
area in figure 3A. Weighting these gains from research 
(figure 3A grey area) by the likelihood that the outcome 
endpoint takes these values (figure 3B red bars) shows 
that research could potentially avert an additional 41 700 
DALYs compared with implementation without research.
The results of conducting this analysis for both the 
outcomes and cost endpoints are shown in table 1. The 
additional health benefits of research are 41 700 DALYs 
Figure 3 Calculating the value of a study of self- testing in women and men focused on outcomes. (A) shows the net health 
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averted by the outcomes study and 89 400 DALYs averted 
by the cost study. The maximum amount a research 
funder should be willing to spend is US$20.9 million 
for the outcomes study and US$44.7 million for the cost 
study, this suggests that further research is potentially 
valuable in this setting.
So far we have shown how the population health benefits 
of research into self- testing can be quantified using existing 
models and model outputs and without use of advanced 
value of information methods. This does not answer a 
key question facing healthcare decision- makers, which is, 
when is the right time to implement a programme if we are 
uncertain about its net health effects?
Three different policy choices are available to health-
care decision- makers:
 ► Implementation without research: implement 
programme without further research if current 
evidence indicates it is cost- effective.
 ► Implementation alongside research: implement 
programme while conducting research, and consider 
scaling back programme if research shows programme 
does not improve net population health.
 ► Research then implementation: delay decision about 
implementation until research reports.
There are trade- offs to consider when choosing 
between these policies. If we wait until the research 
reports before implementing the programme, we forego 
the benefits of implementation in the meantime. On 
the other hand, if the programme is implemented while 
research is conducted there is a risk that the programme 
is found not to have been worthwhile once research 
findings emerge and is scaled back. This also risks the 
loss of resources where irrecoverable programme setup 
costs are high. In some cases, implementation alongside 
research may not be feasible.
We, therefore, quantified the net health consequences 
of each available choice open to policy- makers, assuming 
the outcomes study takes 3 years to report and the cost 
study 1 year to report. This analysis reflects that under 
the research then implementation policy there will be no 
access to self- testing in the research period, and reflects 
that under both policies involving a research compo-
nent, the benefits of research do not emerge until the 
research reports. The methods for this part of the anal-
ysis are shown in the online supplementary material (see 
online supplementary material S3) and results are shown 
in table 2.
The outcomes study offers the potential to avert 12 400 
additional DALYs if the programme is implemented along-
side research. If programme implementation is delayed 
until research findings emerge then the net DALYs averted 
are 19 900 lower than if self- testing was implemented without 
further research. The benefits of having a programme up 
and running straight away (ie, implementation) exceed 
the benefits from making a more informed decision based 
on improved outcome data but delaying availability of the 
intervention by 3 years.
A cost study is expected to avert approximately 67 000 
DALYs regardless of whether it is implemented along-
side research or implementation is delayed until the cost 
study reports.
Our analysis underestimates the benefits of implemen-
tation alongside research for both the outcomes and 
the cost study. Without conducting additional analyses 
using the transmission model, we could not fully simu-
late the consequences of discontinuing the self- testing 
programme when research did not support continued 
implementation. This would have allowed the long- 
term benefits of the self- testing conducted in the 1 or 3 
year research period to have been captured. Instead, we 
assumed that there were no further benefits of self- testing 
when the programme was discontinued. However, these 
potential missed benefits need to be weighed against 
set- up costs which will represent irrecoverable expen-
ditures in the event that research suggests self- testing 
should be scaled back.
DISCUSSION
In this paper, we have shown how a graphical method 
can be used to estimate the value of research studies 
Table 2 Population health consequences of implementation and research policy choices
Implications of decision making without further research
Expected net DALYs averted by implementation 108 425
Implications of decision making informed by further research Outcomes study   Cost study
Implement testing programme alongside research     
Expected net DALYs averted via research 12 376 66 380
Potential maximum expenditure on study US$6 187 927 US$33 189 959
Total expected net DALYs averted 120 801 174 805
Delay implementation until research reports     
Expected net DALYs averted via research −19 869 66 996
Potential maximum expenditure on study −US$9 934 735 US$33 497 945
Total expected net DALYs averted 88 555 175 421
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without advanced value of information methods. We 
provide a simple excel tool to allow readers to use the 
method. Where time and resources allow, information 
from existing studies, expert elicitation and outputs 
generated from existing cost- effectiveness models can be 
used to inform the calculations. Where the assembly of 
such information is not feasible, the method and tool can 
be used to test how different assumptions influence esti-
mates of the value of research, identify the assumptions 
under which a proposed research study appears worth-
while, and allow decision- makers to consider their plau-
sibility. These methods apply to a wide range of research 
studies aimed to inform programme design in the near- 
term (see online supplementary material S4) and can be 
used to quantify the value of collecting data on different 
endpoints and in different populations. The methods 
are relevant where evidence is expected to be considered 
relevant for decision making in multiple countries. The 
net health benefits of the research can be calculated for 
each country and considered collectively when assessing 
the value of the study.
When evaluating a specific research proposal, it may 
be important to consider, quantitatively or qualitatively, 
other factors that may modify the value of research. 
These include future changes that would modify the net 
DALYs averted by the intervention (eg, anticipated price 
reductions for health technologies), uncertainty around 
whether the research completes and is used to inform 
decisions, the degree to which uncertainty is reduced, 
and the potential for the study to generate additional 
secondary outcome data which may be used in a range 
of ways.4 In this example, we assumed the research study 
was small relative to the population that will benefit from 
the research and did not therefore account for the bene-
fits of self- testing for those enrolled in the study. In some 
contexts, the population health benefits for this group 
are significant (eg, in the case of large studies) and could 
be included in the calculations.40
Findings from the HIV self-testing case study
We applied the graphical method to a case study of HIV 
self- testing. This allowed us to show how existing evidence 
can be used to inform an assessment of the value of a 
future study, and how an assessment of the value of 
further research can be used to guide policy decisions 
relating to programme implementation and research.
This showed that a 1- year cost study is likely to be of 
high value, whereas a 3- year outcomes study offered 
more modest value. The outcomes study is only worth 
conducting if it is run in parallel with implementation. 
Delaying implementation until the outcomes study is 
complete results in worse outcomes than implementing 
self- testing without further research. Overall the results 
suggest that if a decision maker considered setup costs to 
be significant, they may wish to commission a cost study 
and delay implementation of self- testing until it reports. 
If setup costs are not considered significant, running a 
cost and outcomes study alongside implementation may 
be the preferred option.
The value of research is fundamentally an economic 
question, as research that aims to inform programme 
design can only deliver value if there is a chance that 
its results could change the assessment about whether 
a programme’s benefits outweigh the opportunity costs. 
The cost per DALY averted threshold used to determine 
the health opportunity costs imposed by programme 
costs is a key driver of this assessment. We used a value 
of US$500/DALY to reflect the opportunity cost of HIV 
service funding. This value is subject to uncertainty and 
our conclusions will differ if a different estimate of oppor-
tunity cost is used. This emphasises the need for both 
resource allocation and research prioritisation decisions 
to be based on a robust assessment of the opportunity 
cost of healthcare funds. Recent work has estimated the 
cost per DALY averted for general (ie, not HIV specific) 
healthcare spending in a range of countries.13 Using 
the estimate generated for Malawi of US$138/DALY13 
within our analysis results in research no longer gener-
ating value. The health opportunity costs of dedicating 
funding to the self- testing programme become so high 
that even under optimistic scenarios about the outcomes 
and costs of testing, the programme will not produce 
positive net population health benefits. This may become 
relevant as funding of HIV services becomes more reliant 
on domestic rather than overseas funding.
The estimates presented reflect the impact of the 
self- testing studies for population health in Malawi. It 
is possible that the research could be used to inform 
resource allocation decisions in additional countries 
with similar local epidemiology and healthcare seeking 
behaviours. If this is the case, we will underestimate the 
value of the studies. Where a research study is expected to 
be used in a number of countries the approach described 
above can be extended to reflect the total global value 
of the research. The value of the study in each country 
can be estimated accounting for differences in the size 
of the population that stand to benefit from research, 
the costs and health benefits of the intervention and the 
cost- effectiveness threshold. This will generate estimate 
of the value of research in each country which can then 
be aggregated to estimate the global value of research.4 41 
A worked example of this is provided in Woods et al.42
Using estimates of the net DALYs averted by research to 
inform research prioritisation
Using estimates of the net DALYs averted by research to 
inform research prioritisation as suggested here is likely 
to require substantive changes to how evidence is used to 
support research funding decisions.
Currently, research funding decisions do not routinely 
use the type of evidence discussed in this paper. Insti-
tutional changes are required to facilitate use of the 
methods. This could include requiring funding bids 
to include these types of analyses, funders themselves 
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decision- makers within LMICs conducting analyses to 
inform the specification of research calls. Research to 
explore how this might work in practise is ongoing in 
high- income settings2 6 43 and further work to assess this 
in LMICs is warranted.
Our case study focused on HIV where both evidence 
and detailed cost- effectiveness models are often well 
developed. In many contexts, models used to assess 
cost- effectiveness will be available and can be used and 
extended to make the value of information assessments 
described here. For decisions where available evidence 
is sparse, cost- effectiveness analyses unavailable, or colla-
tion of such evidence is not feasible, our work can be used 
to test the sensitivity of the value of research to different 
plausible assumptions. This may be sufficient to deter-
mine whether research should be funded. If decisions 
about research appear sensitive to different plausible 
assumptions then there may be value in low- level initial 
research funding to assemble existing evidence, conduct 
expert elicitation and develop basic cost- effectiveness 
analysis and make a more informed assessment of the 
value of research.
The robustness of any estimates of value of information 
will depend on the use of appropriate priors to repre-
sent uncertainties in the available evidence, the credi-
bility of the underlying cost- effectiveness model, and use 
of an appropriate measure of health opportunity costs. 
Specification of each element is likely to require judge-
ments regarding approach and input parameters. By 
using quantitative methods such as those set out here, 
the judgements are open to empirical challenge thus 
allowing for more accountable decision making. When 
cost- effectiveness analyses are used to support service 
investments this often involves an iterative process 
whereby relevant stakeholders review key judgements, 
and scenarios are presented exploring the implications 
of different judgements. We envisage a similar deliber-
ative decision- making process could be usefully imple-
mented when using value of information estimates to 
inform research prioritisation.
Ultimately, once an assessment of the potential popu-
lation health benefits of a research study has been made, 
a research funder will have to assess whether the value 
offered by the research is sufficient to justify the opportu-
nity costs imposed by funding the research. These oppor-
tunity costs depend on potential alternative uses for 
those research funds which may include other research 
and non- research investments. This raises the question 
of how the research funder should assess the opportunity 
costs of their research funds when prioritising between 
funding applications. One way of doing this is to ensure 
only those proposals with the lowest research cost per 
net DALY averted are funded, that is, a cost- effectiveness 
league table approach for research proposals. The net 
DALYs averted by research estimated using the methods 
presented here could be used alongside the research 
costs to generate this information. In the absence of 
this evidence, a useful but imperfect starting point is to 
assume that the opportunity cost of research funds and 
service funds is similar. We have used this assumption 
within this work to estimate the maximum a research 
funder should be willing to spend on a study. Where 
research costs are known this assumption can be used to 
translate research costs to health opportunity costs which 
can be directly compared with the net health benefits 
of research. Those proposals offering the largest differ-
ence between net health benefits of research and health 
opportunity costs of research funding may be considered 
particularly attractive to research funders.
CONCLUSION
Our work provides a method for estimating the health 
benefits of research in a practical and timely fashion. 
This can be used to prioritise funding of those research 
and evidence generation activities that offer real poten-
tial to improve population health.
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